Zobrazeno 1 - 10
of 203
pro vyhledávání: '"Matteo Molica"'
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 6050-6060 (2024)
High-risk acute myeloid leukemia has been associated with a poor outcome. Hematopoietic stem cell transplantation (HSCT) represents the only curative option for eligible patients. Relapse after HSCT is a dramatic event with poor chances of survival.
Externí odkaz:
https://doaj.org/article/7d2a0582d8b74d75be61630a44c107e4
Autor:
Matteo Molica
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 16, Iss 1 (2024)
Limited data are available on the effectiveness of gilteritinib as a third-line salvage therapy in patients with acute myeloid leukemia (AML). We present an elderly patient who achieved sustained remission following gilteritinib monotherapy as a thir
Externí odkaz:
https://doaj.org/article/cb19f72701254c149f9627c3c52f331a
Autor:
Matteo Molica, Carla Mazzone, Tiziana Ottone, Pasquale Niscola, Elisabetta Abruzzese, Stefano Fratoni, Maria Teresa Voso, Paolo de Fabritiis
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Relapses of acute promyelocytic leukemia (APL) beyond 7 years from the first molecular remission are exceptional, and it is unclear whether these relapses represent a new, therapy-related leukemia rather than a delayed relapse of the original leukemi
Externí odkaz:
https://doaj.org/article/13eb7ea5889a49d9b7c036cd2c66e420
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
TP53 is a key tumor suppressor gene with protean functions associated with preservation of genomic balance, including regulation of cellular senescence, apoptotic pathways, metabolism functions, and DNA repair. The vast majority of de novo acute myel
Externí odkaz:
https://doaj.org/article/8fa1d20f76eb4aada41722a1224bb57a
Publikováno v:
Cancer Drug Resistance. 6:223-38
FMS-related tyrosine kinase 3 (FLT3) mutations, present in about 25%-30% of acute myeloid leukemia (AML) patients, constitute one of the most frequently detected mutations in these patients. The binding of FLT3L to FLT3 activates the phosphatidylinos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c252a4252bc716477eea6984bf79ea0
https://doi.org/10.20517/cdr.2022.130
https://doi.org/10.20517/cdr.2022.130
Autor:
Matteo Molica, Nelida I. Noguera, Malgorzata Monika Trawinska, Giovanni Martinelli, Claudio Cerchione, Elisabetta Abruzzese
Publikováno v:
Hematology Reports, Vol 12, Iss s1 (2020)
In addition to the best possible overall survival, discontinuation of the tyrosine kinase-inhibitor (TKI) treatment [treatment free remission (TFR)] without observing a recurrence of the disease has become a standard part of chronic myeloid leukemia
Externí odkaz:
https://doaj.org/article/783cf85ac13a4a109fc411aec9851a84
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 12, Iss 1 (2020)
Chronic myeloid leukemia (CML) is characterized by the presence of the BCR-ABL1 fusion gene. In more than 95% of CML patients, the typical BCR-ABL1 transcript subtypes are e13a2 (b2a2), e14a2 (b3a2), or the simultaneous expression of both. Other less
Externí odkaz:
https://doaj.org/article/83ffc74b93c743239a3a78552f8319cd
Publikováno v:
Therapeutic Advances in Hematology, Vol 10 (2019)
There are five tyrosine kinase inhibitors (TKIs) that are currently approved (in the European Union and the United States) for the treatment of chronic myeloid leukaemia (CML) in the chronic phase (CP) and each of them has its own efficacy and toxici
Externí odkaz:
https://doaj.org/article/74d4f11ae6e94a2ab75db0e02338e563
The traditionally dismal outcome of acute myeloid leukemia (AML) patients carrying the FMS-related tyrosine kinase 3 (FLT3) mutations has been mitigated by the recent introduction of tyrosine kinase inhibitors (TKI) into clinics, such as midostaurin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c4a76e174a61ab7ea6938be6d272767
https://doi.org/10.20944/preprints202304.1236.v1
https://doi.org/10.20944/preprints202304.1236.v1
Autor:
Matteo Molica, Marco Rossi
Publikováno v:
Polish Archives of Internal Medicine. 133
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a96dbf80bf3a9566be583ccf93359a4
https://doi.org/10.20452/pamw.16416
https://doi.org/10.20452/pamw.16416